Health Canada to review AstraZeneca’s COVID-19 prevention drug – National

AstraZeneca has requested Well being Canada to evaluate a brand new long-acting antibody mixture that may very well be used to stop symptomatic COVID-19.

If accepted, it will be the primary antibody safety of its variety in Canada.

Learn extra:
AstraZeneca COVID-19 drug prevents extreme illness if given early, firm says

The corporate says its medical trials confirmed the antibody therapy was nicely tolerated and diminished the danger of growing symptomatic COVID-19 by 77 per cent in comparison with a placebo.

AstraZeneca Canada says it may very well be a superb possibility for susceptible populations who aren’t in a position to develop a robust protecting response from a vaccine.

Click to play video: 'Health Canada considers Merck’s experimental COVID-19 drug'

Well being Canada considers Merck’s experimental COVID-19 drug

Well being Canada considers Merck’s experimental COVID-19 drug – Oct 4, 2021

The corporate says preliminary findings present the antibodies neutralize current COVID-19 variants, together with the Delta and Mu variants.

Story continues beneath commercial

Well being Canada has stated all COVID-19 vaccine and drug submissions might be prioritized and reviewed on an expedited timeline.

Learn extra:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug

© 2021 The Canadian Press

Source link


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button